Clinical Trials Logo

Filter by:
NCT ID: NCT06091488 Active, not recruiting - ACL Injury Clinical Trials

Evaluation Of Clinical Results And Imaging Of Anterior Cruciate Ligament Reconstruction With Orthopure Xt

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate subjective and objective clinical outcomes and imaging data of subjects undergoing reconstruction or revision of LCA reconstruction using OrthoPure XT

NCT ID: NCT04944030 Active, not recruiting - Lung Cancer Clinical Trials

Clinico-biological Data Collection Study of Metastatic Lung Cancer

EPICURE_LUNG
Start date: April 12, 2023
Phase: N/A
Study type: Interventional

RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and biopathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.

NCT ID: NCT05207397 Active, not recruiting - Alzheimer Disease Clinical Trials

Lactate for Energy and Neurocognition

LEAN
Start date: April 12, 2023
Phase:
Study type: Observational

The investigator has shown that improved cardiorespiratory fitness following an aerobic exercise program elicits cognitive benefit in elderly subjects and memory improvement in Alzheimer's disease (AD). The physiological mechanism may be related to exercise-mediated change in circulating factors that permeate the brain. The response to each individual bout of exercise (i.e. the acute exercise response) may differ between subjects and be key to driving brain benefit. In young populations, the acute response to exercise can last hours and affect brain glucose metabolism. However, the field knows little about this acute exercise response in AD. Most exercise intervention trials designed to prevent and slow AD, including our own (AG033673; AG034614; AG043962; AG049749; AG053952), assess biomarkers at two fasting time points: pre- and post-intervention. The acute exercise response in the brain and periphery likely varies between subjects and diagnoses and provide key information regarding mechanisms of benefit. Our primary goals are to characterize the acute exercise response to exercise in the brain (glucose metabolism) and periphery (biomarker response) in aging and AD. The investigator will identify relationships between exercise-related factors (i.e. heart rate, biomarkers) and change in brain metabolism and cognition. Understanding these mechanistic relationships will provide specific targets that can be used in future trials to develop individualized exercise prescriptions and maximize benefit. Accumulating evidence suggests that the exercise-related metabolite lactate is an understudied effector of brain health. Lactate is an essential fuel for neuronal function. It is supplied to neurons through glucose metabolism in nearby glia and from peripheral blood, since the brain is permeable to lactate. A drop in cerebral glucose metabolism is a marker of AD. Thus, supplying neurons directly with lactate for oxidation may supplement energy requirements in AD, as has been suggested with ketones. Importantly, circulating lactate levels rise during exercise. Repeated increases in systemic lactate (acute exercise response) may transiently spare glucose by providing an alternative fuel. With routine exercise, acute responses may elicit adaptations that facilitate the use of lactate beyond that which occurs during acute exercise and contribute to brain benefits observed during chronic exercise interventions. In younger populations, higher exercise intensity evokes a greater lactate response compared to lower intensities and elicits cognitive benefit. The investigator will achieve these goals through the following aim: Aim 1. Examine differences in lactate metabolism between diagnosis groups and the effect of lactate on cognitive performance. Increased blood lactate can reflect increased production or decreased uptake. This has never been compared in ND and AD. The investigator will use a "lactate clamp" procedure, where lactate is infused to concentrations that match those found during exercise, to characterize lactate turnover. The investigator will characterize cognitive performance following lactate infusion, independent of exercise factors. The investigators hypothesize that ND subjects (n=12) will use lactate more efficiently (greater uptake) than AD individuals (n=12). The investigator further hypothesize that cognitive performance will acutely improve after lactate infusion in ND and AD subjects. The overall goal is to characterize lactate metabolism, and its relationships with cognition. The KU ADC is a recognized leader in the study of exercise and metabolism in aged and AD populations, and puts the investigator in a strong position to successfully achieve these aims.

NCT ID: NCT05528562 Active, not recruiting - Opioid Use Disorder Clinical Trials

Pre-exposure Prophylaxis (PrEP) Rapid Access

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

The goal of phase 1 is to determine the feasibility and acceptability of an intervention ('Rapid PrEP Access') providing people who use drugs (PWUD) one-time access to HIV self-testing at the Victory Program. Aim 1: To offer HIV self-testing to PWUD in the community through a study called 'Rapid PrEP Access'. The study will be carried out at the Victory Program. Aim 2: To determine the feasibility and acceptability of 'Rapid PrEP Access' at the Victory Program.

NCT ID: NCT05805722 Active, not recruiting - Cancer Clinical Trials

Comprehensive Tobacco Cessation for Cancer Patients and Survivors

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn how best to incorporate tobacco cessation treatment into clinical care for cancer patients, survivors, and caregivers.

NCT ID: NCT05866120 Active, not recruiting - Parkinson Disease Clinical Trials

Effects of Land and Water Physiotherapy on Motor Function in Parkinson's Disease

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

Parkinson's disease patients have characteristic postural changes in upper limbs, lower limbs and trunk. The presence of kyphosis is observed as the most common postural deformity. The aim of this study is to verify the effect of dry soil therapy and shallow water therapy on muscle function in individuals with Parkinson's disease? Regarding the benefits, is there a difference between the therapies?

NCT ID: NCT05898971 Active, not recruiting - Clinical trials for CVA (Cerebrovascular Accident)

Robotic Hand on Hand Functions in Strokes

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

robotic glove training could be a useful aid for these patients. The aim of this study was to investigate the effect of Robotic gloves versus mirror therapy on Hand function in patients with cerebral vascular accident .

NCT ID: NCT05987163 Active, not recruiting - Skin Manifestations Clinical Trials

Study to Evaluate the Safety and Effectiveness of GP0116

NLF
Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This is a prospective, randomized, evaluator-blinded, comparator-controlled, parallel group, multicenter study in the U.S. for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs).

NCT ID: NCT05754710 Active, not recruiting - Clinical trials for Polyarticular Juvenile Idiopathic Arthritis

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

KRXeljanzJIA
Start date: April 12, 2024
Phase:
Study type: Observational

This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study. Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea. This study is seeking patients who: - Are 2 to less than 18 years of age; - Are given Xeljanz for the treatment of JIA. The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.

NCT ID: NCT06167083 Active, not recruiting - Clinical trials for Carbapenem Resistant Bacterial Infection

Machine Learning in the ICU: Predicting Mortality in Bloodstream Infections (ICU:Intensive Care Unit)

ICU
Start date: April 12, 2024
Phase:
Study type: Observational

Using our own patient data, our study aimed to predict mortality that can develop in Carbapenem-resistant Gram-negative bacilli bloodstream infections with a machine learning-based model. In the intensive care unit, patients with bloodstream infections, both with and without mortality, will be examined retrospectively in two subgroups for comparison.